{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT SAEs (HOSTED)"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP006"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th 12 November 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th11 November 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R& D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "05/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn, R & D Director and Clinic Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "12th November 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: November 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 11,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Bryan Singizi"
                    },
                    {
                        "text": "Oncology Research Nurse"
                    },
                    {
                        "text": "05/07/2019 05/07/2019"
                    },
                    {
                        "text": "Lizzie Dawson"
                    },
                    {
                        "text": "Oncology Research Nurse"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "SOP-01- SOP on SOPs SOP-02- SAEs (Sponsored) SOP-05- Trial Master File SOP-06- Research Staff Training SOP-08- Amendments SOP-09- Serious Breaches (Sponsored)"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "12th November 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "CONTENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Applicable"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "Urgent Safety Measures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "Pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "Related documents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "prefix": 9.0,
                "text": "Equality Impact Assessment  7 Appendix 1.0 Definitions Appendix 2.0 SAE reporting flowchart"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Appendix  Urgent Safety Measures form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "text": "Appendix 4.0 Pregnancy Report Form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "text": "Appendix 5.0 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the adverse event reporting procedures to be followed by all staff who are involved in setting up and running research studies managed by Mid Essex Hospital Services NHS Trust (MEHT)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "It provides guidance on the responsibilities delegated to the Chief Investigator (CI) by the sponsor regarding adverse event reporting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "This SOP relates to Serious Adverse Event (SAE) recording and reporting requirements for MEHT hosted Clinical Trial for an Investigational Medicinal Product (CTIMP). This SOP describes the procedures for identifying, recording and reporting adverse events and serious adverse events. The reporting requirements for SAEs to the Principal investigator (PI), Sponsor and the R&D Office are described."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee (including those with an honorary research contract or letter of access) involved with clinical research including, Chief Investigators (CI), Principal Investigators, Consultants, Clinical Trial Pharmacists, Research Managers, Statisticians, Research Nurses, Research Midwives, Allied Health Professionals, Trial Coordinators, Administrative Staff & Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "For Trust sponsored drug trials, the responsibility for pharmacovigilance is delegated to the CI. The CI should ensure the pharmacovigilance responsibilities are delegated to appropriately trained and qualified individuals and is recorded in a delegation log as described in SOP-06. Throughout this document, this delegated individual will be referred to as \u2018DI'."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "The CI shall also ensure that all study personnel involved in conducting sponsored trials attend SOP training sessions provided by the R&D Office and evidence of this maintained with the study personnel training files (SOP-07)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Recording and Reporting Adverse Events (AE)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "5.1.1 An adverse event (AE) is any untoward medical occurrence in a subject to whom a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "text": "5.1.2 An adverse reaction (AR) is any untoward and unintended response in a subject to an investigational medicinal product which is related to any dose administered to that subject."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "text": "5.1.3 All adverse events and adverse reactions should be recorded in the source data (medical records or case report forms (CRFs or eCRF)), as stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "5.1.4 Adverse events and adverse reactions should be reviewed by a clinician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "5.1.5 The severity of adverse events and adverse reactions should also be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version stated in the protocol. Please ensure that the highest grading is used for recording purposes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "text": "5.1.6 The PI/DI should ensure compliance for assessing adverse events and adverse reactions as described in the Sponsor agreement and protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "text": "5.1.7 Events considered serious, should follow procedures outlined in 5.2."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 1,
                "text": "5.1.8 Adverse Events of Special Interest \u2013  This is a noteworthy event for the particular product or class of products that a sponsor may wish to monitor carefully. It could be serious or non-serious (e.g. hair loss, loss of taste, impotence), and could include events that might be potential precursors or prodromes for more serious medical conditions in susceptible individuals. Such events should be described in protocols or protocol amendments, and instructions provided for investigators as to how and when they should be reported to the sponsor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Recording and Reporting Serious Adverse Events"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "5.2.1 A Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) must be recorded and reported according to the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "5.2.2 An SAE or SAR is:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "Any untoward medical occurrence or effect that at any dose that results in:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "death"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "is life-threatening\u2020"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "requires hospitalisation or prolongation of existing hospitalisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "results in persistent or significant disability or incapacity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "is a congenital anomaly or birth defect"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "is an important medical event"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 1,
                "text": "\u2020 \u201clife-threatening\u201d refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 1,
                "text": "5.2.3 Seriousness assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 1,
                "text": "The PI or DI (Delegated Individual) should review whether the event is serious, i.e. if the event results in one or more of the criteria listed above or has been identified within the protocol or reference document (e.g. Investigator's Brochure (IB) or Summary of Product Characteristics (SPC) as an SAE."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "5.2.4 Any research staff who observes an SAE is responsible for notifying the PI or DI within 24 hours of knowledge, or, as stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "5.2.5 The PI or DI should record the event as stated in the protocol (e.g. CRF/SAE form)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "5.2.6 SAEs and SARs must also be reported to the sponsor within 24 hours, or within the timeframes stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 1,
                "text": "5.2.7 Causality assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "The PI or DI should assess the causality of the event, by considering whether the event has any relationship to the administered study medication, as follows:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 1,
                "text": "\u25cf Events which are  Definitely, Probably or Possibly  related are Serious Adverse Reactions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 1,
                "text": "\u25cf Events which are Unlikely or Unrelated are Serious Adverse Events"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 1,
                "text": "5.2.8 Expectedness assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 1,
                "text": "Generally, the  expectedness assessment is completed by the sponsor. However, for reporting purposes, the CI or DI should assess the expectedness using the reference safety information stated in the protocol (IB or SPC). Serious adverse reactions should be considered as unexpected if the nature, seriousness, severity or outcome of the reaction(s) is not consistent with the reference information for the IMP."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "text": "5.2.9 Current versions of the SPC should be printed and a hard-copy kept in the Trial Master File (TMF). Research teams should check periodically for updates to the SPC in the Electronic Medicines Compendium website."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "5.2.10 IBs should either be kept in the site file or in a central file with a file note stating the current version and its location."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "5.2.11 When IBs are updated with no change to the risk benefit ratio or the safety information, please send a copy to the R&D Office for notification."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "5.2.12 When IBs are updated with a change to the safety information, this should be treated as a substantial amendment (SOP-09). An electronic copy of the IB should also be forwarded to the R&D Office with the associated documentation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "5.2.13 Electronic copies of the IB should be sent to the R&D Office."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "5.2.14 Where electronic copies are not available, a hard-copy of the front sheet should be forwarded to the R&D Office."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "5.2.15 The PI or DI should ensure that the seriousness, causality and severity assessments are documented according to the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "5.2.16 SAEs and SARs must be reported to the sponsor within  hours of knowledge, or as stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "5.2.17 SAEs should be followed-up until resolution or as stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "5.2.18 The SAE flow chart (appendix 2) can be used to assess SAEs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "5.2.19 The R&D Department will monitor SAEs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Recording and Reporting SUSARs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "5.3.1 Events identified as serious, related and unexpected, should be classed as Suspected Unexpected Serious Adverse Reactions (SUSARs) and should be reported to the sponsor within 24 hours of knowledge, or as stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "5.3.2 The sponsor will decide if a SAR or an SAE is a SUSAR and will inform the authorities accordingly."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "5.3.3 If there is any suspicion that a Non-IMP interacts with an IMP, then this should be reported to the sponsor as a possible SUSAR."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "5.3.4 The R&D Department will monitor SAEs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "URGENT SAFETY MEASURES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "An urgent safety measure taken by the Sponsor or Investigator in order to protect the subjects of a clinical trial against any immediate hazard to their health or safety."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "The PI or DI must notify the Sponsor immediately should they believe that an urgent safety measure needs to be implemented."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "prefix": 6.3,
                "text": "The MHRA and HRA must be notified by the Sponsor immediately, and in any event within 3 days, that such a measure has been taken and the reasons why it has been taken."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "prefix": 6.4,
                "text": "Urgent Safety Measures may be taken without prior notification to the MHRA / HRA. However, the PI or DI must inform the R&D Office of the new events, the measures taken and the plan for further action as soon possible."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "prefix": 6.5,
                "text": "If an Urgent Safety measure form has not been provided by the Sponsor, a form for notifying the R&D Office of Urgent Safety Measures is attached as Appendix 3.0."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "PREGNANCY"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Pregnancy in itself is not regarded as an adverse event unless there is suspicion that the study medication may have interfered with the effectiveness of the contraceptive or that it might be harmful to the foetus."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "prefix": 7.2,
                "text": "Should a pregnancy occur, it should be recorded and reported in accordance with the procedures described in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "prefix": 7.3,
                "text": "In the event of a pregnancy, a pregnancy report form should be completed with the PI/DI's signature and sent to the Sponsor. Should the Sponsor not provide a form, please use the Pregnancy Notification Form (attached as Appendix 4)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "prefix": 7.4,
                "text": "The mother should be followed-up during the course of the pregnancy and the baby should be followed-up for a minimum of three months after birth, or as"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "prefix": 7.5,
                "text": "The mother should give consent for additional follow-up during the course of the pregnancy and once the baby is born."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "prefix": 7.6,
                "text": "Similarly, if the partner of a patient on a clinical trial becomes pregnant, the baby should be monitored for at least three months after birth. Consent needs to be obtained for this additional follow-up."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "prefix": 7.7,
                "text": "Any event meeting the serious criteria (death, life-threatening, congenital abnormality, birth-defects) should be reported as an SAE, according to the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "RELATED DOCUMENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "\u25cf SOP-01- SOP on SOPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "\u25cf SOP-02- SAEs (Sponsored)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "\u25cf SOP-05- Trial Master File"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "\u25cf SOP-06- Research Staff Training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "\u25cf SOP-08- Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "\u25cf SOP-09- Serious Breaches (Sponsored)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "\u25cf EC Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (CT-3) (2011/C 172/01)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Detailed guidance on the request to the competent authorities of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end-of-trial (CT-1). (2010/C 82/01)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 5)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) - Any untoward medical occurrence in a patient or clinical trial subject administered a  medicinal product and  which  does not necessarily  have  a causal relationship with this treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 1,
                "text": "Adverse Reaction (AR) - All untoward and unintended responses to an Investigational medicinal product related to any dose administered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) - The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated (DI) by the PI to carry out the task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contract (HRC) - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 1,
                "text": "Pharmacovigilance -  The regulations outline procedures for the recording and reporting of adverse events or suspected unexpected serious adverse reactions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) -  The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 1,
                "text": "Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) - Any untoward medical occurrence or effect that at any dose those results in:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "text": "\u25cf death"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "\u25cf is life-threatening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "text": "\u25cf requires hospitalisation or prolongation of existing hospitalisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "\u25cf results in persistent or significant disability or incapacity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "text": "\u25cf is a congenital anomaly or birth defect"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "text": "\u25cf is an important medical event"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 1,
                "text": "Suspected Unexpected Serious Adverse Reaction (SUSAR) -  All suspected adverse reactions related to an investigational medicinal product (IMP) that is both unexpected and serious."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: SAE reporting flowchart"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "text": "Please carry out the following assessments for all adverse events."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "text": "Seriousness assessment (to be done by a"
            }
        },
        {
            "type": "image",
            "sequence_num": 125,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "text": "delegated clinician)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 0,
                "text": "Was the event listed as a notable event or was the"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "text": "event serious, resulting in: Adverse Event or Adverse Reaction"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "text": "Death NO Record in the source documents i.e. Life-threatening medical records, CRF, as stated in the Required in-patient hospitalisation or  protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "text": "prolongation of hospitalisation?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "text": "Persistent or significant disability or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "text": "incapacity?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "text": "A congenital abnormality or a birth"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "text": "defect?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 1,
                "text": "YES Exempt SAE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "YES 1. Record on the AE log or as stated in Was the SAE described in the protocol as being  the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "text": "exempt from expedited reporting?  2. Record on the SAE on EDGE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 0,
                "text": "NO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 1,
                "text": "dCausalitelegatedy a clissenicissmentan) (to be done by a  NO Serious Adverse Event (SAE)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "text": "1. Record as per protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 1,
                "prefix": 24.0,
                "text": "Was the SAE suspected to be caused by the  Notify C.I. or D.I. within  hours of protocol medication?  knowledge."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 0,
                "text": "3. Record on the SAE on EDGE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 0,
                "text": "YES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 1,
                "text": "Expectedness assessment (to be done by a delegated clinician)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 1,
                "text": "Was the SAR expected, i.e. was it described in the protocol, Investigator's Brochure or the Summary of Product Characteristics as being one of the recognised side effects of the drug?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "text": "NO YES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 0,
                "text": "Research and Development SAEs (hosted)/ MEHTSOP006/ 1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 1,
                "text": "Suspected Unexpected Serious Adverse Reaction (SUSAR)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 1,
                "text": "Serious Adverse Reaction (SAR)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Notification of Amendment for Urgent Safety Measures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 1,
                "text": "Please complete this form to the R&D Office as soon as possible after implementation of Urgent Safety Measure. This form should only be in exceptional circumstances, for example to protect the participants from an immediate hazard to their welfare or safety"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 1,
                "text": "Part A \u2013 Where to Send your Request"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 1,
                "text": "To:  R&D Office  R&D Office use"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 1,
                "text": "only"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "Date received:"
            }
        },
        {
            "type": "image",
            "sequence_num": 157,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.004.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 1,
                "text": "Part B \u2013 Your Details"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "text": "Fro m:"
            }
        },
        {
            "type": "image",
            "sequence_num": 160,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.005.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "Tel:   Fax:"
            }
        },
        {
            "type": "image",
            "sequence_num": 162,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.008.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "Email :"
            }
        },
        {
            "type": "image",
            "sequence_num": 164,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.009.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 1,
                "text": "Part C \u2013 Sponsor Details (please tick)  Trust-sponsored"
            }
        },
        {
            "type": "image",
            "sequence_num": 166,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.010.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "text": "Trust-hosted (please specify below)"
            }
        },
        {
            "type": "image",
            "sequence_num": 168,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.013.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 1,
                "text": "Part D \u2013 Study Details Trial Name:"
            }
        },
        {
            "type": "image",
            "sequence_num": 170,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.015.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 1,
                "text": "CTIMP OR non-CTIMP (please delete as appropriate)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 0,
                "text": "RD reference number:  RD"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 0,
                "text": "Chief Investigator:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 0,
                "text": "Principal Investigator:"
            }
        },
        {
            "type": "image",
            "sequence_num": 175,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.017.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 1,
                "text": "Part E \u2013 Urgent Measures"
            }
        },
        {
            "type": "table",
            "sequence_num": 177,
            "data": {
                "num_rows": 3,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Measures taken:"
                    },
                    {
                        "text": "Date effective from:"
                    },
                    {
                        "text": "Why have these measures been taken:"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator Signature"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 1,
                "text": "Date"
            }
        },
        {
            "type": "image",
            "sequence_num": 180,
            "data": {
                "url": "MEHTSOP006 Research and Development SAEs (hosted) 1.0.019.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 1,
                "text": "Appendix 4: Pregnancy Notification Form"
            }
        },
        {
            "type": "table",
            "sequence_num": 182,
            "data": {
                "num_rows": 6,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "RD number _ _ _ _ Your reference"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Short title of study"
                    },
                    {
                        "text": "Chief Investigator Department"
                    },
                    {
                        "text": "Patient's Trial ID Number __ __ __ __ Date of birth ___ ___ / ___ ___ /___ ___"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 183,
            "data": {
                "num_rows": 16,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "MATERNAL INFORMATION"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Date of Birth _ _/_ _/_ _ _ _ Date of last menstrual period _ _/_ _/_ _ _ _ Expected Date of Delivery _ _/_ _/_ _ _ _ Method of contraception: Was contraception used as instructed? Yes No Uncertain"
                    },
                    {
                        "text": "MEDICAL HISTORY"
                    },
                    {
                        "text": "Include information in familial disorders, known risk factors or conditions that may affect the outcome of the pregnancy. (If none, mark as N/A)"
                    },
                    {
                        "text": "PREVIOUS OBSTETRIC HISTORY"
                    },
                    {
                        "text": "(provide details on all previous pregnancies, including termination or stillbirth) Gestation Week Outcome including any abnormalities 1 2 3"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Patient's Trial ID Number __ __ __ __ Date of birth ___ ___ / ___ ___ /___"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "DRUG INFORMATION"
                    },
                    {
                        "text": "Drug name"
                    },
                    {
                        "text": "Dose"
                    },
                    {
                        "text": "Route"
                    },
                    {
                        "text": "Date start"
                    },
                    {
                        "text": "Date stopped"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 184,
            "data": {
                "num_rows": 14,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "PRENATAL INFORMATION"
                    },
                    {
                        "text": "Have any specific tests, e.g. amniocentesis, ultrasound, maternal serum AFP, been performed during the pregnancy so far? Yes No Not known If Yes, please specify test date and results: Test type and date _ _/_ _/_ _ _ _ Result"
                    },
                    {
                        "text": "PREGNANCY OUTCOME"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Patient's Trial ID Number __ __ __ __ Date of birth ___ ___ / ___ ___ /___ ___"
                    },
                    {
                        "text": "MATERNAL PREGNANCY ASSOCIATED EVENTS"
                    },
                    {
                        "text": "If the mother experiences an SAE during the pregnancy, please indicate here and complete an SAE form, complete with CI's signature."
                    },
                    {
                        "text": "CHILD OUTCOME"
                    },
                    {
                        "text": "(a) Abortion Yes No If Yes Therapeutic Planned Spontaneous"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 185,
            "data": {
                "num_rows": 17,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Please specify the reason and any abnormalities (if known): Date _ _/_ _/_ _ _ _"
                    },
                    {
                        "text": "(b) Delivery Yes No If Yes Normal Forceps/Ventouse Caesarean Date of delivery _ _/_ _/_ _ _ _ Delivery at week: Delivery was: Normal Abnormal Stillborn Please give dates and details of any abnormalities"
                    },
                    {
                        "text": "Sex Male Female Height cm Weight kg Head circumference cm AGPAR score 1minute _ _ 5 minutes _ _ 10 minutes _ _"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Patient's Trial ID Number __ __ __ __ Date of birth ___ ___ / ___ ___ /___"
                    },
                    {
                        "text": "___"
                    },
                    {
                        "text": "ASSESSMENT OF SERIOUSNESS (OF PREGNANCY OUTCOME)"
                    },
                    {
                        "text": "Not serious Serious : a) Mother died/baby died b) Life-threatening c) Involved prolonged inpatient hospitalisation d) Results in persistent or significant disability/incapacity e) Congenital anomaly/birth defect f) Other significant medical events Date of death: _ _/_ _/_ _ _ _"
                    },
                    {
                        "text": "ASSESSMENT OF CAUSALITY(OF PREGNANCY OUTCOME)"
                    },
                    {
                        "text": "Please indicate the relationship between the trial drugs and the pregnancy outcome"
                    },
                    {
                        "text": "Causality"
                    },
                    {
                        "text": "Definitely"
                    },
                    {
                        "text": "Probably"
                    },
                    {
                        "text": "Possibly"
                    },
                    {
                        "text": "Unlikely"
                    },
                    {
                        "text": "Unrelated"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Trial Drug(s)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 186,
            "data": {
                "num_rows": 5,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Could the trial drugs have interfered with contraception? a) Yes b) No c) Maybe"
                    },
                    {
                        "text": "ANY ADDITIONAL INFORMATION"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "DETAILS OF PERSON SUBMITTING THIS REPORT"
                    },
                    {
                        "text": "Signature \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 Date _ _/_ _/_ _ _ _ Please print name \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. CI/PI signature\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 Date _ _/_ _/_ _ _ _"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 0,
                "text": "Research and Development SAEs (hosted)/ MEHTSOP006/ 1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 0,
                "text": "Research and Development SAEs (hosted)/ MEHTSOP006/ 1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 1,
                "text": "Appendix 5: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research and Development SAEs (hosted)/ MEHTSOP006"
            }
        },
        {
            "type": "table",
            "sequence_num": 192,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 194,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 0,
                "prefix": 17.0,
                "text": ""
            }
        }
    ]
}